Publications directory

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm

The web Directory of Information Materials for People Affected by Cancer is regularly updated and currently has details of over 1,900 booklets, leaflets, books and audiovisual materials for people affected by cancer. Most have been published in the last five years but we have included some older ones that are still useful.

Results: 1190

Cover image of 'Thrombocytopenia (low platelets)'

Thrombocytopenia (low platelets) (February 2019)

Lymphoma Action

People with lymphoma sometimes have thrombocytopenia because of the lymphoma itself or as a side effect of treatment. This can put them at a higher risk of bleeding and bruising. This factsheet explains what thrombocytopenia is and why people with lymphoma get thrombocytopenia and describes the symptoms, treatment and how to reduce the risk of bleeding.

Cover image of 'Thalidomide'

Thalidomide (January 2019)

Myeloma UK

This treatment guide has information about thalidomide, a drug used in the treatment of myeloma. It explains  what it is, how it works, and how it is given, and describes the possible side-effects.

Cover image of 'Zoledronic acid for primary breast cancer'

Zoledronic acid for primary breast cancer (April 2019)

Breast Cancer Care

Zoledronic acid is a drug that’s given to reduce the risk of breast cancer spreading to the bones and other parts of the body. This booklet explains what it is, who might be offered it and the side effects it can cause.

Cover image of 'Sex and fertility'

Sex and fertility (November 2019)

Orchid – Fighting Male Cancer

This leaflet describes sperm banking and how different treatment options for testicular cancer may affect a man’s fertility.

Cover image of 'Melflufen (Ygalo®)'

Melflufen (Ygalo®) (December 2019)

Myeloma UK

Melflufen is a new drug being investigated in the treatment of myeloma. It is a derivative of the chemotherapy drug melphalan. This factsheet explains what melflufen is, how it works, and the current evidence to support its use in the treatment of myeloma. It also describes the known possible side-effects, and the availability of melflufen in the UK.

Cover image of 'Cyclophosphamide'

Cyclophosphamide (January 2019)

Myeloma UK

Cyclophosphamide is a chemotherapy drug used in the treatment of myeloma. It belongs to a class of chemotherapy drugs called alkylating agents. This factsheet describes what it is, how it works, how it is given, and possible side-effects.

Cover image of 'Isatuximab'

Isatuximab (December 2019)

Myeloma UK

Isatuximab is a new drug that is being investigated for the treatment of myeloma. This factsheet describes briefly what it is, how it works, how it is given, the possible benefits over existing drugs, the possible side-effects, and its availability in the UK.

Cover image of 'Venetoclax (Venclyxto®)'

Venetoclax (Venclyxto®) (August 2019)

Myeloma UK

This factsheet has information on venetoclax, a drug being investigated for the treatment of patients with the t(11;14) type of myeloma. It explains what venetoclax treatment is, how it works, and the current evidence to support its use in the treatment of myeloma. It also describes the known possible side-effects, and the availability of venetoclax in the UK.

Cover image of 'Lenalidomide (Revlimid®)'

Lenalidomide (Revlimid®) (January 2019)

Myeloma UK

Lenalidomide, also known as Revlimid®, is an immunomodulatory drug (IMiD) used in the treatment of myeloma.This factsheet describes what it is, how it works, how it is given, and possible side-effects.

Cover image of 'Hair loss'

Hair loss (September 2019)

Lymphoma Action

Some lymphoma treatments can cause your hair to thin or fall out. Knowing what to expect and what you can do about it may help you cope with losing your hair. This factsheet has advice on how to care for your hair and scalp during and after treatment. It also tells you about some of the options you may wish to consider until your hair grows back. 

Sorry, no publications found.
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm